Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

8.2%

19 terminated/withdrawn out of 231 trials

Success Rate

84.9%

-1.6% vs industry average

Late-Stage Pipeline

18%

42 trials in Phase 3/4

Results Transparency

11%

12 of 107 completed trials have results

Key Signals

43 recruiting12 with results15 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 1

125(54.8%)

Phase 2

60(26.3%)

Phase 3

41(18.0%)

Phase 4

1(0.4%)

N/A

1(0.4%)

228Total

Phase 1(125)

Phase 2(60)

Phase 3(41)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (231)

Showing 20 of 231 trials

NCT06081920Phase 2Recruiting

A Study of IBI363 in Subjects With Advanced Melanoma

Role: lead

NCT07731607Phase 2Not Yet Recruiting

Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer

Role: collaborator

NCT07122687Phase 2Recruiting

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Role: lead

NCT07722494Phase 3Not Yet Recruiting

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

Role: lead

NCT07591519Phase 1Recruiting

Clinical Trials of IBI3035 in Healthy Subjects

Role: lead

NCT07449481Phase 2Withdrawn

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Role: collaborator

NCT07622368Phase 1Recruiting

A Study of IBI3031 in Participants With Thyroid Eye Disease

Role: lead

NCT07217301Phase 3Recruiting

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Role: collaborator

NCT05991349Phase 1Completed

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT06184568Phase 3Completed

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Role: lead

NCT06947408Phase 1Completed

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants

Role: lead

NCT07559019Phase 1Recruiting

Safety and Preliminary Activity of BI115 in Advanced SCLC

Role: lead

NCT07623798Phase 3Not Yet Recruiting

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Role: lead

NCT07483554Phase 2Recruiting

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Role: lead

NCT07483567Phase 2Recruiting

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Role: lead

NCT05890742Phase 3Active Not Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Role: lead

NCT07612137Phase 1Not Yet Recruiting

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT07469800Phase 3Recruiting

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Role: lead

NCT07295496Phase 1Active Not Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

Role: lead

NCT07456839Phase 1Active Not Recruiting

A Mutiple-dose Study of IBI3033 in Healthy Participants

Role: lead